Revisiting Liver Monitoring During Methotrexate Therapy in Rheumatoid Arthritis: Implications of HBV Reactivation, MASLD, and Non-invasive Fibrosis Assessment

Clicks: 8
ID: 330783
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #44 of 47 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Liver function monitoring remains a cornerstone of safety surveillance during methotrexate (MTX) therapy for rheumatoid arthritis (RA). Traditionally, monitoring has focused on hepatitis B virus (HBV) reactivation and chronic MTX hepatotoxicity. Because HBV persists in hepatocytes as covalently closed circular DNA (cccDNA) even after apparent clinical resolution of infection, all individuals with previous HBV exposure remain at risk of viral reactivation. Accordingly, screening for previous HBV infection before initiating MTX is essential, and regular monitoring of HBV DNA should be considered in patients with resolved or chronic HBV infection. Close collaboration with hepatology specialists is required to ensure timely initiation of nucleos(t)ide analogue therapy when indicated. In contrast, the conventional concept of chronic MTX-induced hepatotoxicity has been increasingly challenged. Recent studies employing non-invasive fibrosis assessment tools have demonstrated little or no association between cumulative MTX dose or treatment duration and the progression of liver fibrosis. These findings suggest that severe chronic liver injury caused solely by MTX is uncommon and that the hepatotoxic potential of MTX may have been substantially overestimated. Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide and appears to be at least as prevalent among patients with RA than in the general population. Therefore, evaluation and management of MASLD should be considered as part of routine clinical care for patients with RA. Because liver fibrosis is the most important determinant of long-term hepatic outcomes, monitoring strategies should incorporate fibrosis assessment using non-invasive tools such as the fibrosis-4 (FIB-4) index and elastography-based liver stiffness measurement.
Reference Key
openalex_W7215057561 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ryuji Koike, Yuji Yamanishi, Mie Fusama, Shigeru Iwata, Masahiro Tada, Haruka Tsuchiya, Kunihiro Yamaoka, Hideto Kameda
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag085
URL
https://doi.org/10.1093/mr/roag085
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.